The potency of tissue-type plasminogen activator (TPA) determined with chromogen and clot-lysis assays.
An assessment was made of two methods for determining the potency of tissue-type plasminogen activator (TPA). A chromogenic microtitre plate assay was established which contained TPA, plasminogen, a synthetic plasmin substrate (H-D-valyl-L-leucyl-L-lysyl-p-nitroaniline dihydrochloride, S2251) and any one of the following stimulators: native fibrinogen, enzymatic and chemical digests of fibrinogen, poly-D-lysine (PDL) and chemical derivatives of the latter. The chromogen assay was compared with an automated clot-lysis (turbidimetric) assay for sensitivity, reproducibility and validity for potency determination. Reference preparations of TPA were titrated in both assays: in the chromogen assay the dose-response curves were non-parallel, whereas parallelism was observed in the clot-lysis assay. Thus, the chromogen assay was restricted in its applicability and disqualified from any routine regulatory use. The potency of individual lots of recombinant (r)TPA could only be estimated in International Units (IU) of TPA activity with the automated clot-lysis assay and the potency values obtained (IU/vial) were in remarkably close agreement with the manufacturers' values.
Christodoulides
M
M
Blood Products Division, Bureau of Biologics, Ottawa, Ontario, Canada.
Boucher
D W
DW
D002863:Chromogenic Compounds; D005069:Evaluation Studies as Topic; D005340:Fibrinogen; D005342:Fibrinolysis; D009842:Oligopeptides; D011107:Polylysine; D011994:Recombinant Proteins / Q000032:analysis / Q000592:standards; D012015:Reference Standards; D010959:Tissue Plasminogen Activator / Q000032:analysis* / Q000592:standards
D002863:Chromogenic Compounds; D009842:Oligopeptides; D011994:Recombinant Proteins; D011107:Polylysine; C018788:valyl-leucyl-lysine 4-nitroanilide; D005340:Fibrinogen; D010959:Tissue Plasminogen Activator